IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues warning letter to Sun Pharma's API plant in India

3:38 AM MDT | May 21, 2014 | Deepti Ramesh

FDA issued a warning letter on 7 May to the active pharmaceutical ingredient (API) and finished pharmaceutical manufacturing facilities of Sun Pharmaceutical Industries (Sun Pharma; Mumbai)—located at Karkhadi, Vadodara District, India—for violations of cGMP. The warning letter was published on the FDA Web site on 20 May. An FDA inspection from 13–16 November 2013 at the Karkhadi facility identified deviations from cGMP for the manufacture of APIs and the violation of cGMP regulations for finished pharmaceuticals, FDA says. An import alert was...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa